Dedicated to biobased BTX
BioBTX B.V. was founded to develop efficient and effective technologies , for the production of biobased BTX (the molecules benzene, toluene and xylene, also called aromatics; high volume chemical building blocks normally made from petrochemicals) as well as bio-oil. In accomplishing this BioBTX will contribute considerably to making the chemical and plastics industry more sustainable.
The very large and important chemical industry is struggling to move towards sustainability, which in many cases especially means a shift to biomass based feedstock. For certain chemical products this shift is already possible, however at present there is no commercially available technology to produce biomass-based aromatics (benzene, toluene and xylenes, together also called BTX). Aromatics are indispensable building blocks for plastics such as PET and nylon, polyurethane, coatings and many more. Around 40% of the raw materials used in the chemicals industries are BTX. Yearly 100 million tons of aromatics are being produced. This volume is growing rapidly due to demand, especially in developing countries.Bio
AGILeBiotics starts antibiotic discovery and development program
Since decades, natural product-based antibiotics are the number one choice for the treatment of patients infected by bacteria. However, rising bacterial resistance limits the clinical application of these promising drugs worldwide. To reinstall their clinical use, AGILeBiotics employs its smart and patented synthetic method OxaSelect that converts existing antibiotics, which lost their efficacy, to novel antibiotic derivatives overcoming bacterial resistance. With this unique technology, AGILeBiotics evades the discovery step and gives promising antibiotics a second life cycle.
AGILeBiotics is a spin-off company of the University of Groningen located in Groningen in the North of the Netherlands. The company is located in the InnoLab Chemie that offers state of the art laboratory facilities for start-up companies. All technologies AGILeBiotics is employing were co-invented and established at the University by the CEO of AGILeBiotics Dr. Andreas A. Bastian. Supported by the University of Groningen and the University Medical Center Groningen (UMCG), AGILeBiotics is developing its own drug pipeline of novel antibiotics to treat multidrug resistant infections.